Discovery and development of heat shock protein 90 inhibitors.

Article Details

Citation

Copy to clipboard

Taldone T, Sun W, Chiosis G

Discovery and development of heat shock protein 90 inhibitors.

Bioorg Med Chem. 2009 Mar 15;17(6):2225-35. doi: 10.1016/j.bmc.2008.10.087. Epub 2008 Nov 6.

PubMed ID

19017562 [ View in PubMed

]

Abstract

Heat shock protein 90 (Hsp90) is an important target in cancer because of its role in maintaining transformation and has recently become the focus of several drug discovery and development efforts. While compounds with different modes of action are known, the focus of this review is on those classes of compounds which inhibit Hsp90 by binding to the N-terminal ATP pocket. These include natural product inhibitors such as geldanamycin and radicicol and synthetic inhibitors comprised of purines, pyrazoles, isoxazoles and other scaffolds. The synthetic inhibitors have been discovered either by structure-based design, high throughput screening and more recently using fragment-based design and virtual screening techniques. This review will discuss the discovery of these different classes, as well as their development as potential clinical agents.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine	Heat shock protein HSP 90-beta	EC 50 (nM)	15000	N/A	N/A	Details
9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine	Heat shock protein HSP 90-beta	IC 50 (nM)	1000	N/A	N/A	Details